Abstract
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung
Volume 8, Number 3 (Apr 2017)
https://doi.org/10.6004/jadpro.2017.8.3.9
